ARTIFICIAL INTELLIGENCE-ENHANCED LIQUID BIOPSY IN CANCER MONITORING: FROM TREATMENT RESPONSE TO EARLY DETECTION OF DISEASE RECURRENCE
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6672Keywords:
Artificial Intelligence, Liquid Biopsy, Cancer Recurrence, Precision OncologyAbstract
Liquid biopsy has emerged as an important minimally invasive technology in contemporary oncology, enabling repeated assessment of tumor-derived molecular information through blood and other biological fluids. Circulating tumor DNA (ctDNA), circulating tumor cells, cell-free DNA methylation patterns, extracellular vesicles, circulating RNA and fragmentomic signatures may provide dynamic information about tumor burden, treatment response, molecular residual disease and cancer recurrence. However, liquid biopsy generates complex, multidimensional datasets in which tumor-derived signals may be extremely small relative to biological and technical background. Artificial intelligence (AI), including machine learning and deep learning, offers a potential computational framework for integrating these heterogeneous signals and generating clinically meaningful predictions.
This review examines the emerging convergence of AI and liquid biopsy, with particular emphasis on longitudinal cancer monitoring rather than cancer detection alone. The available PubMed-indexed literature was reviewed to evaluate the potential role of AI-enhanced liquid biopsy in treatment-response assessment, minimal residual disease detection, prediction of treatment resistance and early identification of disease recurrence. Evidence from colorectal, lung, breast, hepatocellular and other solid tumors is discussed. The review also addresses major translational barriers, including low tumor shedding, clonal hematopoiesis, analytical heterogeneity, external validation, algorithmic bias, interpretability, data privacy, cost and uncertainty regarding clinical actionability. Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation. AI-enhanced liquid biopsy may ultimately support a transition from episodic, imaging-centered surveillance toward personalized, dynamic and molecularly informed cancer monitoring.
References
Association for Molecular Pathology, & College of American Pathologists. (2024). Recommendations for cell-free DNA assay validations: A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. The Journal of Molecular Diagnostics.
Bartolomucci, A., Nobrega, M., Ferrier, T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025). Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precision Oncology, 9, 84. https://doi.org/10.1038/s41698–025–00876-y
Chen, Y., Mo, S., Wu, M., Li, Y., Chen, X., & Peng, J. (2022). Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence: A systematic review and meta-analysis. International Journal of Colorectal Disease, 37, 1021–1027. https://doi.org/10.1007/s00384–022–04144–4
Choi, Y., Dharia, N. V., Jun, T., Chang, J., Royer-Joo, S., Yau, K. K., Assaf, Z. J., Aimi, J., Sivakumar, S., Montesion, M., Sacher, A., LoRusso, P., Desai, J., Schutzman, J. L., Shi, Z., et al. (2024). Circulating tumor DNA dynamics reveal KRAS G12C mutation heterogeneity and response to treatment with the KRAS G12C inhibitor divarasib in solid tumors. Clinical Cancer Research, 30(17), 3788–3797. https://doi.org/10.1158/1078–0432.CCR-24–0255
Filis, P., Markozannes, G., Salgkamis, D., Tsiknakis, N., Zerdes, I., Pagkalidou, E., Manou, M., Filis, N., Papakonstantinou, A., Mavroudis, D., Matikas, A., Tsilidis, K. K., & Foukakis, T. (2026). Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis. European Journal of Cancer, 239, 116699.
He, X., Liu, X., Zuo, F., Shi, H., & Jing, J. (2023). Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Seminars in Cancer Biology, 88, 187–200. https://doi.org/10.1016/j.semcancer.2022.12.009
Hitchen, N., Shahnam, A., & Tie, J. (2025). Circulating tumor DNA: A pan-cancer biomarker in solid tumors with prognostic and predictive value. Annual Review of Medicine, 76, 207–223. https://doi.org/10.1146/annurev-med-100223–090016
Lockwood, C. M., Messersmith, H. J., Kim, A. S., Rajagopal, P. S., Swami, U., Xian, R., Aisner, D., Arcila, M. E., Kurttila, F., Lovly, C. M., Merker, J. D., Nair, K. G., Ntekim, A. I., Sheen, M. A., Tsimberidou, A. M., Turner, N. C., & Gray, S. W. (2026). Circulating tumor DNA testing in solid tumors and lymphoma: ASCO guideline. JCO Oncology Practice. https://doi.org/10.1200/OP-26–00311
Li, A., Lou, E., Leder, K., & Foo, J. (2025). Early circulating tumor DNA kinetics as a dynamic biomarker of cancer treatment response. JCO Clinical Cancer Informatics, 9, e2400160. https://doi.org/10.1200/CCI-24–00160
Liu, C.-Y., Lin, Y.-H., Tsai, Y.-F., et al. (2026). Circulating tumor cells enumeration and machine-learning based diagnostic biomarkers for breast cancer detection. BMC Cancer, 26, 448.
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bagga, P., & Meral, R. (2022). Liquid biopsy: A step closer to transform diagnosis, prognosis and future of cancer treatments. Molecular Cancer, 21, 79.
Markou, A., Tzanikou, E., & Lianidou, E. (2022). The potential of liquid biopsy in the management of cancer patients. Seminars in Cancer Biology, 84, 69–79. https://doi.org/10.1016/j.semcancer.2022.03.013
Mathios, D., et al. (2024). Cell-free DNA fragmentomics in cancer. Cancer Cell.
Nader-Marta, G., Monteforte, M., Agostinetto, E., Cinquini, M., Martins-Branco, D., Langouo, M., Llombart-Cusac, A., Cortés, J., Ignatiadis, M., Torri, V., Apolone, G., Cappelletti, V., Pruneri, G., de Azambuja, E., & Di Cosimo, S. (2024). Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: A systematic review and meta-analysis. ESMO Open, 9(3), 102390. https://doi.org/10.1016/j.esmoop.2024.102390
Nikanjam, M., Kato, S., & Kurzrock, R. (2022). Liquid biopsy: Current technology and clinical applications. Journal of Hematology & Oncology, 15, 131. https://doi.org/10.1186/s13045–022–01351-y
Reinert, T., et al. (2025). Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: The randomized phase 2/3 DYNAMIC-III trial. Nature Medicine.
Shibuki, T., Yamashita, R., Hashimoto, T., Fujisawa, T., Imai, M., Yuda, J., Kuwata, T., Misumi, T., Nakamura, Y., Bando, H., Kojima, K., Tokioka, S., Chiba, I., Nakaya, N., Hozawa, A., Koshiba, S., Fuse, N., Saito, S., Shimizu, R., Park, W.-Y., Kinoshita, K., & Yoshino, T. (2026). Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI). International Journal of Clinical Oncology, 31(5), 843–850. https://doi.org/10.1007/s10147–026–03001–6
Sisca, L., Polito, M. G., Sisca, E., Iuliani, M., Cortellini, A., Vincenzi, B., Tonini, G., & Pantano, F. (2026). Artificial intelligence-enabled liquid biopsy in cancer: A systematic review and meta-analysis of diagnostic performance and biological implications. Frontiers in Oncology, 16, 1850705. https://doi.org/10.3389/fonc.2026.1850705
Tang, L., Li, R., Wen, H., Zhou, Q., & Xu, C. (2023). Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer. Chinese Medical Journal Pulmonary and Critical Care Medicine, 1(4), 207–214.
Tébar-Martínez, R., et al. (2023). Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treatment Reviews, 119, 102595. https://doi.org/10.1016/j.ctrv.2023.102595
Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., Wong, R., Shapiro, J., Lee, M., Harris, S., Khattak, A., Burge, M., Harris, M., Lynam, J., Nott, L., Day, F., Hayes, T., McLachlan, S.-A., Lee, B., Ptak, J., Silliman, N., Dobbyn, L., Popoli, M., Hruban, R., Lennon, A. M., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Tomasetti, C., & Gibbs, P. (2022). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. New England Journal of Medicine, 386(24), 2261–2272. https://doi.org/10.1056/NEJMoa2200075
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., Kosmider, S., Skinner, I., Wong, R., Steel, M., Tran, B., Desai, J., Jones, I., Haydon, A., Hayes, T., Price, T. J., Strausberg, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P. (2016). Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 8(346), 346ra92. https://doi.org/10.1126/scitranslmed.aaf6219
Tsui, W. H. A., Ding, S. C., Jiang, P., & Lo, Y. M. D. (2025). Artificial intelligence and machine learning in cell-free-DNA-based diagnostics. Genome Research, 35(1), 1–19.
Valenza, C., Saldanha, E. F., Gong, Y., De Placido, P., Gritsch, D., Ortiz, H., Trapani, D., Conforti, F., Cremolini, C., Peters, S., Mateo, J., Subbiah, V., Parsons, H. A., Partridge, A. H., & Curigliano, G. (2025). Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: A systematic review and meta-analysis. Annals of Oncology, 36(7), 726–736. https://doi.org/10.1016/j.annonc.2025.03.019
Wang, Y., Xiang, Y.-B., Chen, X.-W., Zhang, T., Wang, J.-Y., Liu, W.-Y., Deng, L., Wang, L.-H., Gao, S.-G., & Bi, N. (2026). PRIME: An interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer. Journal of Hematology & Oncology, 12(1), 94. https://doi.org/10.1186/s40779–025–00679-z
Xia, J., Zhang, J., Xiong, Y., Zhao, J., Zhou, Y., Jiang, T., & Zhu, J. (2023). Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer. Expert Review of Molecular Diagnostics, 23(10), 913–924. https://doi.org/10.1080/14737159.2023.2252334
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Vanessa Gąsiorowska, Karolina Grodkowska-Szukała , Ewa Jachimczak, Natalia Smyczyńska, Ewa Wojtanowska, Paulina Jaruga, Julia Paczyna, Julia Kozicka, Mateusz Michalak, Marcin Mazur
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
